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Edited by Richard CogdellAbstract The TIR domain-containing adapter protein TRIP is
critically involved in TLR3-induced IFN-b production through
activation of NF-jB and ISRE. In addition, TRIF also induces
apoptosis when overexpressed in 293 cells. In this report, we
demonstrate that PIASy, a member of the PIAS SUMO-ligase
family, interacts with TRIP, IRF-3 and IRF-7. In reporter gene
assays, PIASy dramatically inhibits TRIF-induced NF-jB,
ISRE and IFN-b activation but not TRIF-induced apoptosis.
Furthermore, PIASy also inhibits IRF-3, IRF-7 and Sendai
virus-induced ISRE activation. Our results suggest that PIASy
is an inhibitor of TRIF-induced ISRE and NF-jB activation but
not apoptosis.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The Toll/interleukin-1 receptor (TIR) family members are
evolutionary conserved proteins that are critically involved in
innate immunity [1–3]. This family of receptors contains a
conserved cytoplasmic TIR domain that is required for their
signaling leading to activation of transcription factors NF-jB,
ATF-2/c-Jun and IRFs, and subsequent induction of various
chemokines and cytokines that are involved in host defense
against the pathogens [1–3].
The TIR family receptors signal through conserved path-
ways. Upon ligand stimulation, TIR family receptors recruit
TIR domain-containing adapter proteins to the receptor sig-
naling complexes. So far, there are four TIR domain-con-
taining adapter proteins, including MyD88, TIRAP/Mal,
TRIF/TICAM and TIRP/TRAM, which have been cloned [4–
10]. These proteins have distinct and overlapping roles in TIR
signaling.
Among the TIR domain-containing adapters, TRIF is un-
ique in that it can activate both NF-jB and ISRE. A dominant
negative mutant of TRIF inhibits both TLR3-mediated NF-
jB and ISRE activation [8,9]. Recently, TRIF-deﬁcient mice
were produced by gene knock-out and chemical mutagenesis
approaches [11,12]. These studies indicated that TRIF-deﬁ-
cient mice were defective in both TLR3- and TLR4-mediated* Corresponding author. Fax: +1-303-398-1396.
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NF-jB through a TRAF6-dependent pathway and activates
ISRE through IRF-3 and IRF-7 [13–16]. Two serine/threonine
protein kinases, IKKe and TBK1, have been shown to be in-
volved in phosphorylation and activation of IRF-3 and IRF-7
[14–16]. Recently, it has also been shown that TRIF can induce
apoptosis through a RIP-FADD-caspase-8-dependent and
mitochondria-independent pathway [16].
Protein inhibitors of activated STAT (PIAS) family mem-
bers were originally identiﬁed as inhibitors of STAT proteins.
In mammals, ﬁve members (PIAS1, PIAS3, PIASxa, PIASxb
and PIASy) have been identiﬁed [17]. PIAS1 and PIAS3 have
been shown to bind and inhibit STAT1 and STAT3 DNA-
binding activities, respectively [17,18]. PIASxa and PIASxb are
probably derived from alternatively spliced mRNA products
of the same gene. PIASxa interacts with the androgen receptor
and regulates its activity [19,20]. PIASxb interacts with the
homeodomain protein Msx2 [21]. PIASy can inhibit STAT1-,
Smad-, GATA-2, c-Myb or androgen receptor-mediated
transcriptional responses without blocking their DNA-binding
activities, [22–26] and repress LEF1 activity by sequestration
into nuclear bodies [27]. In addition, the PIAS family members
have been shown to act as SUMO-E3 ligases, which promote
covalent addition of a small ubiquitin-related modiﬁer to a
target protein [19,20,27].
In this paper, we investigated the roles of one PIAS family
member, PIASy, on TRIF signaling. Our ﬁndings suggest that
PIASy negatively regulates TRIF-induced NF-jB and ISRE
activation but not TRIF-induced apoptosis.2. Materials and methods
2.1. Reagents
Human embryonic kidney 293 cells and Sendai viruses were pur-
chased from ATCC (Manassas, VA). The monoclonal antibodies
against the FLAG and HA epitopes were purchased from the Sigma
company (St. Louis, MO).
2.2. Constructs
ISRE luciferase reporter construct, pFR-luciferase and pFA2-c-Jun
vectors were obtained from Stratagene (La Jolla, CA). NF-jB lucif-
erase reporter construct (Dr. Gary Johnson, University of Colorado
Health Sciences Center) and mammalian expression plasmid for
FLAG-TRAF6 (David Goeddel, Tualrik Inc.) were provided by the
indicated investigators; IFN-b luciferase reporter construct, and
mammalian expression plasmids for FLAG- or HA-tagged TRIF,
IRF-3 and IRF-7 were previously described [5,16]. Mammalian ex-
pression plasmid for Flag-tagged PIASy was constructed by PCR.blished by Elsevier B.V. All rights reserved.
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293 cells (2 105) were seeded on 6-well (35-mm) dishes and were
transfected the following day by the standard calcium phosphate
precipitation [28]. Within the same experiment, each transfection was
performed in triplicate, and where necessary, empty control plasmid
was added to ensure that each transfection receives, the same amount
of total DNA. To normalize for transfection eﬃciency, 0.3 lg of
RSVb-gal plasmid was added to each transfection. Luciferase reporter
assays were performed using a Luciferase Assay Kit (BD PharMingen)
and following the manufacturer’s protocols, b-galactosidase activity
was measured using the Galacto-Light Chemiluminescent Kit (TRO-
PIX, Bedford, MA). Luciferase activities were normalized on the basis
of b-galactosidase activities.Fig. 1. PIASy inhibits TRIF- and TRAF6-induced NF-jB but not TRAF6
activation in a dose-dependent manner. 293 cells (2 105) were transfected
the indicated amounts of expression plasmids. Reporter gene assays were
detected by Western blot analysis (lower panel). (B) PIASy inhibits TRAF6-in
lg of NF-jB-luciferase and 0.3 lg of RSV-b-gal plasmid and 1 lg of each of
induced c-Jun activation. 293 cells were transfected with pFR-luciferase, pF
assays were performed 16 h after transfection. Data shown are averages and
b-gal activities. The experiments were repeated for at least three times with2.4. Co-immunoprecipitation and Western blot analysis
Transfected 293 cells from each 100-mm dish were lysed in 1
ml of lysis buﬀer (20 mM Tris (pH 7.5), 150 mM NaCl, 1%
Triton, 1 mM EDTA, 10 lg/ml aprotinin, 10 lg/ml leupeptin and
1 mM phenylmethylsulfonyl ﬂuoride). For each immunoprecipita-
tion, 0.4 ml aliquots of lysates were incubated with 0.5 lg of the
indicated monoclonal antibody or control mouse IgG and 20 ll
of a 1:1 slurry of GammaBind G Plus Sepharose (Amersham
Pharmacia, Piscataway, NJ) for at least 1 h. The sepharose beads
were washed three times with 1 ml lysis buﬀer containing 500
mM NaCl. The precipitates were fractionated on SDS–PAGE and
subsequent Western blot analyses were performed as described
[5,16].-induced c-Jun activation. (A) PIASy inhibits TRIF-induced NF-jB
with 0.3 lg of NF-jB-luciferase and 0.3 lg of RSV-b-gal plasmid and
performed (upper panel). The expression of transfected proteins was
duced NF-jB activation. 293 cells (2 105) were transfected with 0.3
the indicated expression plasmids. (C) PIASy does not inhibit TRAF6-
A2-c-Jun, RSV-b-gal and the indicated plasmids. Luciferase reporter
standard deviations of relative luciferase activities normalized based on
similar results.
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293 cells (1 105) were seeded in 6-well dishes and transfected the
next day with 0.5 lg ISRE reporter plasmid and 0.5 lg RSV-b-gal
plasmid. Eighteen hours after transfection, cells were washed with
medium lacking fetal calf serum (washing medium), then overlaid with
washing medium containing Sendai virus at a multiplicity of infection
of 10. After incubation at 37 C for 60 min, non-adsorbed viruses were
removed by repeated washing of the cells. Cells were then cultured
in fetal calf serum-containing medium for 18 h before luciferase and
b-galactosidase assays were performed.
2.6. Apoptosis assays
b-Galactosidase co-transfection assays for determination of cell
death were performed. Brieﬂy, 293 cells (2 105) were seeded on 6-
well (35 mm) dishes and were transfected the following day with 0.1 lg
of pCMV-b-galactosidase plasmid and the indicated testing plasmids.
Within the same experiment, each transfection was performed in
triplicate, and where necessary, enough amount of empty control
plasmid was added to keep each transfection receiving the same
amount of total DNA. Approximately 24 h after transfection, the cells
were stained with X-gal. The numbers of survived blue cells from ﬁve
representative viewing ﬁelds were determined microscopically. Data
shown are averages and standard deviations of one representative
experiment in which each transfection has been performed in triplicate.
2.7. DNA fragmentation assays
Transfected cells were washed twice with cold PBS and lysed with
2% NP-40 containing 0.2 mg/ml Proteinase K. DNA in the lysate was
precipitated with two volumes of ethanol. The pellets were dissolved in
H2O and analyzed by electrophoresis with 1.2% gel.Fig. 2. PIASy inhibits TRIF-, IRF-3-, IRF-7- and Sendai virus-in-
duced ISRE activation. (A) PIASy inhibits TRIF-induced ISRE ac-
tivation. 293 cells (2 105) were transfected with 0.3 lg of ISRE
reporter plasmid, 0.3 lg of RSV-b-gal plasmid and 1 lg of each of
the indicated expression plasmids. Sixteen hours after transfection,
luciferase reporter assays were performed. (B) PIASy inhibits IRF-3-
and IRF-7-induced ISRE activation. Reporter assays were performed
as in A except that TRIF was replaced with IRF-3 or IRF-7 (upper
panel). The expression levels of transfected proteins were detected by
Western blot analysis (lower panel). (C) PIASy inhibits Sendai virus-
induced ISRE activation. 293 cells (1 105) were transfected
with 0.3 lg of ISRE reporter plasmid, 0.3 lg of RSV-b-gal plasmid
and the indicated amounts of an expression plasmid for PIASy.
Eighteen hours after transfection, cells were infected with Sendai
virus or left untreated for additional 18 h before luciferase activities
were measured.3. Results
3.1. PIASy inhibits TRIF-induced NF-jB activation
Previous reports have shown that TRIF activates NF-jB
through TRAF6-IKKb-dependent pathway when overexpres-
sed in mammalian cells [8,9,13,16]. To examine the role of
PIASy in TRIF-mediated NF-jB activation, we performed
transient transfection and reporter gene assays in 293 cells. The
results indicated that PIASy inhibited TRIF-mediated NF-jB
activation in a dose-dependent manner (Fig. 1A). In these
experiments, PIASy did not aﬀect TRIF expression level
(Fig. 1A). TRIF also inhibited TRAF6-mediated NF-jB ac-
tivation (Fig. 1B) but not TRAF6-mediated c-Jun activation
(Fig. 1C). In fact, TRAF6-mediated c-Jun activation was po-
tentiated by PIASy (Fig. 1C).
3.2. PIASy inhibits TRIF-, IRF-3-, IRF-7 and Sendai
virus-induced ISRE activation
Previously, it has been shown that TRIF activates bothNF-jB
and ISRE [8–16]. In reporter gene assays, we found that PIASy
could also inhibit TRIF-, IRF-3- and IRF-7-induced ISRE ac-
tivation (Figs. 2A and B). In these experiments, PIASy also did
not aﬀect the expression levels of IRF-3 and IRF-7 (Fig. 2B).
Infection of target cells with Sendai viruses leads to strong
activation of ISRE and type I interferon production [29]. As
shown in Fig. 2C, Sendai virus-induced ISRE activation was
potently inhibited by PIASy in a dose-dependent manner.
3.3. PIASy inhibits TRIF-induced IFN-b activation
Activation of type I IFNs requires a coordinate activation of
multiple transcription factors, including NF-jB and IRF-3/
IRF-7 [30,31]. It has been shown that TRIF activates both
NF-jB and IRF-3/IRF-7 and is required for TLR3-and
TLR4-induced IFN-b activation [8,9]. In reporter gene assays,
Fig. 3. PIASy inhibits TRIF-induced IFN-b activation. 293 cells
(2 105) were transfected with 0.3 lg of IFN-p-luciferase reporter
construct, 0.3 lg of RSV-b-gal plasmid and the indicated expression
plasmids (1 lg each). Sixteen hours after transfection, luciferase re-
porter assays were performed.
Fig. 4. PIASy has no eﬀects on TRIF-induced apoptosis. (A,B) Eﬀects
of crmA and PIASy on TRIF-induced cell death. 293 cells (2 105)
were transfected with 1 lg of each of the indicated expression plasmids
and 0.1 lg of pCMV-b-gal plasmid. Twenty four hours after trans-
fection, the cells were ﬁxed, stained with X-gal and photographed (A).
The survived blue cells from ﬁve representative viewing ﬁelds were
quantitated by counting under a microscope (B). (C) Eﬀects of crmA
and PIASy on TRIF-induced DMA fragmentation. 293 cells
(1 106) were transfected with either 10 lg of each of the indicated
expression plasmids. DNA was isolated from each sample and ana-
lyzed by agarose gel eletrophoresis.
Fig. 5. PIASy interacts with TRIF, IRF-3 and IRF-7 in mammalian
cells. 293 cells (2 106) were transfected with expression plasmids for
Flag-tagged PIASy, together with HA-tagged TRIF, IRF-3, IRF-7
and TRAF7. Cell lysates were immunoprecipitated with control mouse
IgG, monoclonal anti-Flag or anti-HA antibody. The immunopre-
cipitates were analyzed by Western blots with anti-Flag or anti-HA
antibody, respectively (upper panels). The expression levels of the
transfected proteins were detected by Western blot analysis (middle
and bottom panels).
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inhibit TRIF-induced activation of IFN-b promoter (Fig. 3).
3.4. PIASy has no eﬀects on TRIF-induced apoptosis
Infection of cells with Sendai viruses induces apoptosis [32].
It has been demonstrated that TRIF induces caspase-depen-
dent apoptosis when overexpressed in 293 cells [16]. To de-
termine whether PIASy is involved in TRIF-induced
apoptosis, we performed b-galactosidase co-transfection and
DNA fragmentation assays. In these assays, TRIF-induced
apoptosis was inhibited by the caspase inhibitor crmA but not
by PIASy (Figs. 4A–C).3.5. PIASy interacts with TRIF, IRF-3 and IRF-7 in
mammalian cells
PIAS family members exert their biological eﬀects by di-
rectly interacting with multiple molecules [17–23]. Since PIASy
can inhibit TRIF-induced NF-jB, ISRE and IFN-b activa-
tion, we determined whether PIASy could interact with TRIF,
IRF-3 and IRF-7 in mammalian cells. We transfected 293 cells
with an expression vector for Flag-tagged PIASy together with
an expression vector for HA-tagged TRIF, IRF-3 or IRF-7.
Co-immunoprecipitation and Western blot experiments indi-
cated that PIASy could interact with TRIF, IRF-3 and IRF-7
(Fig. 5). In contrast, a control protein, TRAF7, did not in-
teract with PIASy in these experiments (Fig. 5). These data
suggest that PIASy interacts with TRIF, IRF-3 and IRF-7.4. Discussion
The TIR family members of the innate immune system de-
tect host invasion by pathogens and initiate immune responses.
All of the TIR receptors use the adaptor MyD88 to transduce
a signal; however, three newly identiﬁed signaling molecules,
J. Zhang et al. / FEBS Letters 570 (2004) 97–101 101TIRAP, TRIF and TIRP, interact with a subset of the TLRs,
suggesting a signaling speciﬁcity that may be relevant to the
type of infection [33].
TLR3 recognizes dsRNA generated during viral infection
and is critically involved in host defense against viruses [34].
Activation of TLR results in induction of type I IFNs, in-
cluding IFN-b and IFN-a family cytokines, which are crucial
mediators of the anti-viral response. TRIF is the TIR-domain
containing adapter protein critically involved in TLR3-in-
duced IFN-b production and NF-jB activation [8,9].
Previously, we and others have shown that TRIF activates
NF-jB and ISRE and induces apoptosis through distinct
pathways [8–16]. In this study, we found that PIASy could
inhibit TRIF-induced NF-jB and ISRE activation but not
apoptosis. Interestingly, PIASy could also inhibit NF-jB ac-
tivation induced by TRAF6, a downstream component of
TRIF-induced NF-jB activation pathway. One explanation
for this is that PIASy also targets TRAF6 or a component
downstream of TRAF6.
Previously, it has been reported that PlASy is located pre-
dominantly in the nucleus and interacts with various tran-
scription factors [23,26,27,35]. However, it has also been
reported that PIASy interacts with cytoplasmic proteins, such
as Axin [36]. It has been shown that TRIF is associated with
Toll-like receptor 3 [8,9]. Whether TRIF is transported into the
nucleus is unknown. IRF-3 and IRF-7 are normally located in
the cytoplasm, but are transported into the nucleus upon ac-
tivation [8,9]. Currently, where PIASy interacts with TRIF,
IRF-3 and IRF-7 are unknown.
Previous studies have shown that PIASy can repress tran-
scriptional activities through diﬀerent mechanisms. PIASy in-
hibits STAT1 and androgen receptor activities without
interfering with their DNA-binding activities, whereas the re-
pression of p53 activity appears to be through inhibition of p53
binding to DNA [23,26,35]. On another hand, it has been
shown that the inhibitory eﬀect of LEF1 by PIASy is mediated
by sequestration of LEF1 into nuclear bodies [27]. The
mechanisms responsible for PIASy-mediated inhibition of
TRIF-induced NF-jB and ISRE activation are unknown.
Since PIASy has been shown to function as a SUMO ligase,
whether sumoylation is involved in PIASy-mediated inhibition
of TRIF signaling needs to be further investigated.References
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